Table 4.
Comparison of the Proportion of Patients With at Least 1 Drug Interaction by Therapeutic Class Between 2012 and 2016 (n = 729), McNemar Test
| Non-ARV Treatment Class (CBIP) | 2012, No. (%) | 2016, No. (%) | P Value |
|---|---|---|---|
| Orange flag interactions | |||
| Ear, nose, and throat drugs | 5 (0.5) | 3 (0.4) | .71 |
| Osteoarticular drugs | 19 (2.6) | 17 (2.3) | .67 |
| Cardiovascular drugs | 109 (15) | 92 (12.6) | .081 |
| Gastrointestinal drugs | 6 (0.8) | 6 (0.8) | 1.00 |
| Respiratory drugs | 10 (3.2) | 6 (0.8) | .21 |
| Hemostasis drugs | 23 (3.2) | 25 (3.4) | .70 |
| CNS agents | 57 (7.8) | 47 (6.4) | .20 |
| Analgesics | 20 (2.7) | 20 (2.7) | 1.00 |
| Obstetrics & gynecology | 11 (1.5) | 13 (1.8) | .62 |
| Immunity | 7 (1.0) | 7 (1.0) | 1.00 |
| Anti-infectives | 40 (5.5) | 21 (2.9) | .0056 |
| Antineoplastic agents | 1 (0.1) | 2 (0.3) | .32 |
| Others drugs | 2 (0.3) | 4 (0.6) | .16 |
| Genitourinary drugs | 1 (0.1) | 1 (0.1) | 1.0 |
| Dietary supplements | 15 (2.1) | 49 (6.7) | <.0001 |
| Hormone drugs | 39 (5.4) | 46 (6.3) | .32 |
| Red flag interactions | |||
| Ear, nose, and throat drugs | 4 (0.5) | 2 (0.3) | .32 |
| Osteoarticular drugs | 2 (0.3) | 1 (0.1) | .32 |
| Cardiovascular drugs | 9 (1.2) | 16 (2.2) | .090 |
| Gastrointestinal drugs | 13 (1.8) | 11 (1.5) | .62 |
| Respiratory drugs | 8 (1.1) | 7 (1.0) | .71 |
| Hemostasis drugs | 0 (0.0) | 1 (0.1) | .32 |
| CNS agents | 0 (0.0) | 2 (0.3) | .16 |
Abbreviations: ARV, antiretroviral; CBIP, Belgian Center for Pharmacotherapeutic Information; CNS, central nervous system.